The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 18 of the 25 sources its claims cite were checked for support.
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Open accessPublished version of a preprint
Abstract
Most patients with KRASG12C–mutant non–small cell lung cancer (NSCLC) experience clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To investigate the cause of the limited efficacy of KRASG12C inhibitors in colorectal cancer, we examined the effects of AMG510 in KRASG12C colorectal cancer cell lines. Unlike NSCLC cell lines, KRASG12C colorectal cancer models have high basal receptor tyrosine kinase (RTK) activation and are responsive to growth factor stimulation. In colorectal cancer lines, KRASG12C inhibition induces higher phospho-ERK rebound than in NSCLC cells. Although upstream activation of several RTKs interferes with KRASG12C blockade, we identify EGFR signaling as the dominant mechanism of colorectal cancer resistance to KRASG12C inhibitors. The combinatorial targeting of EGFR and KRASG12C is highly effective in colorectal cancer cells and patient-derived organoids and xenografts, suggesting a novel therapeutic strategy to treat patients with KRASG12C colorectal cancer. Significance: The efficacy of KRASG12C inhibitors in NSCLC and colorectal cancer is lineage-specific. RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance to KRASG12C inhibition in colorectal cancer. EGFR and KRASG12C should be concomitantly inhibited to overcome resistance to KRASG12C blockade in colorectal tumors. See related commentary by Koleilat and Kwong, p. 1094. This article is highlighted in the In This Issue feature, p. 1079
Overview
CoChat Summary
TL;DR
In KRAS G12C colorectal cancer, EGFR signaling drives resistance to KRAS G12C inhibition: CRC cells show high basal RTK activation and rapid phospho-ERK rebound after AMG510, unlike NSCLC. Combining EGFR blockade with AMG510 durably suppresses signaling and induces tumor regression in CRC cell lines, patient-derived organoids, and xenografts.
Key findings
- AMG510 initially downregulated phospho-ERK in all models, but after 24 hours NSCLC lines further downregulated ERK phosphorylation while all CRC lines showed phospho-ERK rebound; in C106, residual phospho-MEK/ERK was measurable after 1 hour, whereas NCIH358 rebound appeared only at 72 hours.
- In 8 CRC and 5 NSCLC KRAS G12C patient specimens analyzed for 72 proteins by SRM-mass spectrometry, EGFR, HER2, and MET were detectable in both lineages, HER3 was more prevalent in CRC, and ALK, ROS1, RET, FGFR, or AXL were not detected; two CRC and two NSCLC patients later treated with AMG510 showed clinical benefit only in the NSCLC cases.
- EGFR was identified as the dominant resistance mechanism: cetuximab plus AMG510 synergized in CRC cell lines, sustained inhibition of phospho-MEK/phospho-ERK and DUSP6/CyclinD1, and induced cytotoxicity; combination was also effective in LIM1215 KRAS G12C knock-in clones and the HCA46-R Pmab secondary-resistance model.
- In patient-derived models, single-agent AMG510 or cetuximab poorly inhibited three KRAS G12C PDOs while the combination suppressed proliferation with high synergy; in two KRAS G12C PDXs, combination treatment induced massive or complete tumor shrinkage, with no tumor visible after 10 weeks, and Ki67 IHC intensity was 97% in vehicle, 92% in cetuximab, and 83% in AMG510 samples, with strong phospho-ERK only in AMG510-treated samples.
Methods
- Preclinical study using KRAS G12C mutant NSCLC and CRC cell lines, dose-response proliferation assays, Western blotting, phospho-RTK arrays, EGFR immunoprecipitation, RAS-GTP pull-down, and SRM-mass spectrometry of 72 biomarkers in FFPE tissue from 8 CRC and 5 NSCLC patient specimens.
- Patient-derived models included three KRAS G12C mutant CRC PDOs plus one KRAS G12D mutant PDO as negative control, and two KRAS G12C mutant CRC PDXs; in vivo dosing was AMG510 100 mg/kg daily by gavage and cetuximab 50 mg/kg twice weekly intraperitoneally, with mice randomized to treatment or vehicle.
- Main analyses included ATP-based CellTiter-Glo viability, CellTox Green cytotoxicity, crystal violet long-term proliferation, Bliss synergy scoring, Ki67 and phospho-ERK IHC, and densitometry with ImageJ and GraphPad Prism.
Limitations
- Stated: the authors note that in clinical samples they could not assess activated RTK levels or evaluate the functional consequences of detectable RTK expression.
- Evident: the clinical correlation rests on only two CRC and two NSCLC patients who later went on the AMG510 phase 1 trial, and the paper does not include a dedicated limitations section.
- Evident: the efficacy of combined EGFR and KRAS G12C inhibition is shown in cell lines, PDOs, and PDXs, not in a clinical trial, and the PDX experiments use small group sizes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 1 Not checked · 69 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“We and others previously reported that KRAS acquired mutations are responsible for secondary resistance to anti-EGFR therapies in CRC(22, 23).”
What the sources say
- Supportedcites [22] Misale, 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature source
The paper states that KRAS mutations are causally responsible for acquired cetuximab resistance in its cell models and identifies them as frequent drivers of acquired resistance in colorectal cancer. It also reports secondary KRAS mutations in 6 of 10 patient cases examined after resistance to cetuximab or panitumumab developed; the claim does not say KRAS accounts for every case. (LLM, conf=0.93)
- Supportedcites [23] Diaz, 2012, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature source
The paper’s Abstract says that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade. It reports detectable KRAS mutations during panitumumab treatment in 9 of 24 patients whose tumors were initially KRAS wild-type. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given this particular feature of the KRAS G12C mutant protein, the efficacy of these compounds can be increased by concomitant receptor tyrosine kinase (RTK) inhibition that further maintain KRAS G12C in a GDP-bound conformation, facilitating the binding of the covalent inhibitor(7-9).”
What the sources say
- Partly supportedcites [7] Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature sourceExperimental — accuracy not yet measured
The paper’s Abstract (page unavailable) reports preferential binding of the inhibitors to GDP-bound K-Ras(G12C) and says GTP loading impairs modification. It does not report that concomitant RTK inhibition maintains the GDP-bound state or increases covalent-inhibitor efficacy. (LLM, conf=0.86)
- Supportedcites [8] Lito, 2016, Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism, Science source
The supplied passages report that inhibiting RTK-mediated nucleotide exchange enhanced the effect of the KRAS G12C inhibitor ARS853 in tested cell lines. They also explain that ARS853 binds GDP-bound KRAS G12C and traps it in that inactive state, supporting the proposed mechanism. The effective RTK target varied by cell line. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [9] Patricelli, 2016, Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state, Cancer Discov source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we used a CRC cell line (HCA46-R Pmab), in which prolonged treatment with panitumumab lead to the emergence of a KRAS G12C allele(24).”
What the sources say
- Supportedcites [24] Misale, 2014, Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer, Sci Transl Med source
The methods description (p. 6) says HCA-46 cells were exposed to panitumumab until resistant populations emerged. The Figure 1 alteration table (p. 23) identifies KRAS p.G12C in the HCA-46 panitumumab-resistant derivative, supporting the claim. (LLM, conf=0.94)
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, the differential activity of EGFR inhibitors in CRC versus NSCLC further indicate signaling differences in these two lineages(33).”
What the sources say
- Supportedcites [33] Troiani, 2016, Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence, ESMO Open source
The Secondary resistance section states that EGFR activation is ligand-mediated in CRC but mutation-driven in NSCLC, directly supporting a difference in signaling. The treatment sections also describe different responses to EGFR inhibitors in molecularly selected CRC and NSCLC patients. Page numbers are unavailable in our copy. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Basal EGFR expression, as measured by immunohistochemistry or mass spectrometry(28, 29), has not been associated with EGFR inhibitor sensitivity in CRC”
What the sources say
- Supportedcites [28] Serna, 2019, Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer, Sci Rep source
The Results section (‘Protein expression as a predictor of clinical benefit with targeted and standard therapies’; page not available) reports no association between EGFR protein levels and response to EGFR-targeted therapy in 23 RAS wild-type patients. This supports the mass-spectrometry finding for which this paper is cited. (LLM, conf=0.90)
- Supportedcites [29] Chung, 2005, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol source
The Discussion reports that EGFR positivity measured by immunohistochemistry had little or no predictive value for cetuximab activity in colorectal cancer, with similar response rates across staining levels. This supports the IHC portion of the sentence; the separate mass-spectrometry citation is not assessed here. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
45 more claims
Create a free account to see all 82 claims and every source verdict.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 12
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the clinical benefit that was observed for many patients treated with KRASG12C inhibitors, acquired resistance to single-agent therapy eventually occurred in most patients.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent work has also highlighted the importance of activation of EGFR and other ERBB family members as an adaptive response and resistance mechanism to KRAS inhibition across cancer types (30, 34, 63).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that vertical inhibition of EGFR and SHP-2 (upstream RAS molecules), suppresses feedback reactivation and has stronger antitumor effects than monotherapy (8,27).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies have shown that inhibiting EGFR can overcome the intrinsic resistance of CRC to KRAS-targeted therapy [79].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, preclinical and clinical evidence suggests that dual targeting of KRAS G12C and EGFR could overcome this resistance mechanism.14”
From Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
54 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ In vivo studies · p. 14
“AMG 510 was given 100mg/kg daily by gavage.”
§ Figure legends · p. 20
“AMG510 100mg/kg oral BID”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ ERK inhibition is not sustained in CRC cell lines treated with AMG510 · p. 4
“seven CRC cell lines”
§ ERK inhibition is not sustained in CRC cell lines treated with AMG510 · p. 4
“(C106, RW7213, SW837, SNU1411, JVE015 and LIM2099)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ In vivo studies · p. 13
“Mice were randomized (n=7 per arm)”
§ Figure legends · p. 20
“Error bars represent SEM (5 animals per group)”
Citations
Cites
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“org IntroductIon The small GTPase KRAS is mutated and constitutively active in 15% of all human tumors (1).”
BackgroundSelf-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 2×
“However, in recent years, the unique characteristics of one of the KRAS-mutant alleles, KRASG12C, have been exploited for the design of covalent inhibitors that can specifically bind the cysteine on the mutant residue (7).”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 2×
“These trials, however, show substantial differences in the response rate between patients with NSCLC and patients with colorectal cancer (14, 15).”
BackgroundResultVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 10×
“CRC0051 PDO A D E F B C KRASG12C KRASG12D Vehicle Ki-67 pERK Cmab AMG510 CTRL AMG510 2.5 µmol/L AMG510 + Cmab Cmab 50 µg/mL CRC1589 PDO CRC1360 PDO IRCC-107-A PDO 140 120 100 % c el l v ia bi lit y (A T P c on te nt ) fo ld c on tr ol 80 60 40 20 0 120 20 10.0 5.0 2.5 1.3 0.6 0.3 0.2 0.1 C R C 00 51 C R C 15 89 C R C…”
BackgroundInfluentialSelf-citationRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 2×
“Guanine exchange factors, such as SOS1, and GTPase activating proteins (GAP), such as NF1, directly mediate KRAS activation (2, 3).”
BackgroundGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903 · cited 1×
“Guanine exchange factors, such as SOS1, and GTPase activating proteins (GAP), such as NF1, directly mediate KRAS activation (2, 3).”
BackgroundEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“We and others previously reported that acquired KRAS mutations are responsible for secondary resistance to antiEGFR therapies in colorectal cancer (22, 23).”
BackgroundSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 10×
“CRC0051 PDO A D E F B C KRASG12C KRASG12D Vehicle Ki-67 pERK Cmab AMG510 CTRL AMG510 2.5 µmol/L AMG510 + Cmab Cmab 50 µg/mL CRC1589 PDO CRC1360 PDO IRCC-107-A PDO 140 120 100 % c el l v ia bi lit y (A T P c on te nt ) fo ld c on tr ol 80 60 40 20 0 120 20 10.0 5.0 2.5 1.3 0.6 0.3 0.2 0.1 C R C 00 51 C R C 15 89 C R C…”
BackgroundInfluentialSaltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · cited 1×
“The anti-EGFR antibodies cetuximab and panitumumab are approved for the treatment of RAS/RAF wild-type colorectal cancer (34, 35), whereas EGFR tyrosine kinase inhibitors (TKI) are approved for the treatment of EGFR-mutant lung cancer (36).”
BackgroundHyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Cited by
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Self-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“…RTK activation and phospho-ERK signaling rebound, which suggests that combining EGFR and KRASG12C inhibitors could potentially overcome resistance (Amodio et al. 2020); (2) the coactivation of multiple RTKs, as observed in other cancers (Stommel et al. 2007); and (3) the possibility that…”
Background
Metadata
- Authors
- Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., Whaley, A., Pinnelli, M., Murciano-Goroff, Y. R., Vakiani, E., Valeri, N., Liao, W.-L., Bhalkikar, A., Thyparambil, S., Zhao, H.-Y., de Stanchina, E., Marsoni, S., Siena, S., Bertotti, A., Trusolino, L., Li, B. T., Rosen, N., Di Nicolantonio, F., Bardelli, A., & Misale, S.
- Affiliations
- Candiolo Cancer Institute (IT)
- Memorial Sloan Kettering Cancer Center (US)
- 3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Institute of Cancer Research (GB)
- 8mProbe Inc., Rockville, Maryland.
- 4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- 1Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
- ORCID
- Amodio, Vito
- Yaeger, Rona
- Arcella, Pamela
- Lamba, Simona
- Lorenzato, Annalisa
- Arena, Sabrina
- Montone, Monica
- Mussolin, Benedetta
- Bian, Yu
- Pinnelli, Marika
- Vakiani, Efsevia
- Valeri, Nicola
- Bhalkikar, Anuja
- Thyparambil, Sheeno
- de Stanchina, Elisa
- Marsoni, Silvia
- Siena, Salvatore
- Bertotti, Andrea
- Trusolino, Livio
- Li, Bob T.
- Rosen, Neal
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Misale, Sandra
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1129-1139
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7416460
- OpenAlex
- W3028041439
- Semantic Scholar
- 661f0115485ce5da1097363ee37b949ce0ca63da
- Cited by
- 504
- References
- 39
- Citations by year
- 2026: 85 · 2025: 88 · 2024: 98 · 2023: 73 · 2022: 81 · 2021: 66 · 2020: 13
- FWCI
- 21.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (20697, 21407, 22802)
- AIRC (IG 2018-ID 21923, 2018-ID 21091, 2017 ID 20236)
- European Research Council (724748)
- H2020 (754923, 731105)
- AIRC CRUK AECC (22795)
- NIH (R01 CA233736)
- Cancer Center Core (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- KRAS G12C, colorectal cancer, EGFR, drug resistance, sotorasib, receptor tyrosine kinase signaling, combination therapy, patient-derived organoids, xenografts
- MeSH terms
- Cetuximab, Animals, Antineoplastic Agents, Female, Humans, Piperazines, Pyridines, Pyrimidines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Mice, SCID, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0187
- The paper
- Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., Whaley, A., Pinnelli, M., Murciano-Goroff, Y. R., Vakiani, E., Valeri, N., Liao, W.-L., Bhalkikar, A., Thyparambil, S., Zhao, H.-Y., . . . Misale, S. (2020). EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.